Project Grant R41AG062163

This Project Grant award of $254,896.00 was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to Glial Therapeutics, LLC. The goal of the project is to test whether pharmacological inhibition of the integrin ITGβ8 using a new humanized monoclonal antibody, ADWA11, can safely and effectively restore microglia-astrocyte responses as a therapy for Alzheimer's disease (AD). The project aims to advance the understanding of how modulating...

This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $156,000 to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, to develop novel therapeutic strategies for suppressing the cGAS-STING pathway in Alzheimer's disease (AD). The project aims to generate intrabodies to neutralize RNA::DNA hybrids that activate the cGAS-STING pathway, leading to neuroinflammation and neuronal death in AD cell models....

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...

This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $252,124 to Alphamemory, LLC to conduct research targeting the substrate of gamma-secretase for selective amyloid reduction in Alzheimer's disease. The key products or services to be delivered include: Structure-activity relationship (SAR) studies and lead optimization of a compound (C1) to improve drug activity and in vitro ADME properties (Aim 1). In vivo...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $504,505 in funding to Bolden Therapeutics Inc. to conduct preclinical characterization of splice-modifying antisense oligonucleotides (ASOs) targeting neurogenesis in human Alzheimer's disease (AD) neural cells. The goal of this Phase I effort is to evaluate lead candidate exon-skipping ASOs in human neural cell culture, with the aim of modulating target expression, altering protein...

This federal Cooperative Agreement award of $1,480,275 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of a novel class of calcium-dependent phospholipase A2 (cPLA2) inhibitors as a potential treatment for Alzheimer's disease (AD) and related neuroinflammatory disorders. The University of Southern California is the prime awardee and will establish a comprehensive structure-based drug discovery platform to identify and optimize new lead compounds...

This $792,498 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports research by the Trustees of Indiana University, doing business as Indiana University Indianapolis, to investigate the role of P2X7 receptor signaling in neuroinflammation and neurodegeneration in Alzheimer's disease and related dementias (ADRD). The key objectives are to: 1) characterize mouse models of ADRD to assess neuroinflammation, synaptic density, and neuronal health...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,432,649 to Virogenics, Inc., a biotechnology company in San Diego, California, to advance the development of CMS121, an innovative drug candidate for the treatment of Alzheimer's disease (AD). The funding will support two key components: 1) A 13-week toxicology study in rats and dogs to enable longer-term clinical trials of CMS121 in human subjects with mild to moderate AD, and 2) The...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...

This $461,146 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports research to investigate the disruption of astrocyte function and its relationship to cognitive decline in Alzheimer's disease (AD). The grant recipient, Yale University, will use novel imaging techniques to longitudinally track changes in astrocytic and neuromodulatory signaling across the cerebral cortex in genetic models of AD. The key objectives are to determine: 1) if early...